What Underpins the Success of Biopharmaceutical CMOs in Europe, Frost & Sullivan answers

29-Nov-2011 - United Kingdom

With outsourcing becoming a strategic issue rather than a mere cost-cutting tool for most Biopharmaceutical companies, it is essential that the CMOs are properly positioned and remain at the forefront of technology to sustain and grow in the capital intensive Biopharmaceutical Contract Manufacturing Market.

The biopharmaceutical contract manufacturing market in Europe has constantly been through alternating cycles of excess and inadequate manufacturing capacities since the establishment of contract manufacturing organisations (CMOs) in the mid-1990s. The current scenario in Europe indicates a marginally excessive supply of capacity over demand and in the future, surplus supply is expected in the long term. As of 2011 a few CMOs are on the verge of capacity expansions for specific projects, and the demand for outsourcing of biopharmaceutical manufacturing is growing at a rate of 15 per cent.

Although, the current scenario indicates a marginally excessive supply of capacity over demand, there is need for additional capacity requirements in future, given the rich pipeline and growth of biosimilars.

“The European biosimilars market is expected to experience significant growth, as almost half the biologics in this space are set to lose their patent protection over the next 10 years, propelling the need for new capacity additions,” observes Aiswariya Chidambaram, Research Analyst at Frost & Sullivan.

While market opportunities abound for CMOs, the careful outweighing of the risks and the benefits of capacity expansion will be the key to success. “Given the current scenario of surplus capacity supply, it is essential that CMOs make cautious decisions regarding capacity expansion and choice of contract deals, lest they be hit by overcapacity and a subsequent erosion of profit margins, “ says Aiswariya Chidambaram.

In the future, an increasing demand for the outsourcing of the biopharmaceutical manufacturing activities to CMOs is anticipated, especially for crucial operations like upstream and downstream processing and fill and finish activities. Europe holds the best track record for the regulatory approval of biosimilars, a market that is expected to contribute a robust growth rate of 49-55 per cent over the next seven years.

Frost & Sullivan has recently organised an on-demand web-conference entitled “What Underpins the Success of Biopharmaceutical CMOs in Europe”. The web-conference summarises Ms Chidambaram’s findings, investigating the technology landscape and establishing an understanding of the current and future trends in the European Biopharmaceutical Contract Manufacturing Market, thus enabling the market participants to make strategic decisions for the future.

https://www.bionity.com/en/news/135420/what-underpins-the-success-of-biopharmaceutical-cmos-in-europe-frost-sullivan-answers.html